Cell Reprogramming via Predictive Transcription Factor Framework
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cell-based regenerative therapy face challenges in efficiently identifying factors for transdifferentiation between cell types, leading to inefficiencies and scalability issues, and there is a need for patient-specific, immunologically-matched cells for therapeutic applications.
Innovation Solution
A predictive framework combining gene expression data with regulatory network information to identify transcription factors necessary for cell conversion, allowing for direct reprogramming of source cells to target cell types by determining differential gene expression and network scores, and ranking transcription factors for effective conversion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exhaustive experimental testing of plausible sets of factors is used to identify transdifferentiation factors, then complete identification of conversion factors is achieved, but the process becomes inefficient and unscalable
Solution Approach 1:
The patent applies preliminary action by using computational algorithms to predict and prioritize transcription factor combinations before experimental testing. The system pre-calculates potential factor sets based on gene expression data and network analysis, allowing researchers to focus experiments on the most promising candidates rather than testing all plausible combinations exhaustively.
Solution Approach 2:
The patent replaces the mechanical experimental testing system with a computational prediction system. By substituting computational algorithms that analyze gene expression data and regulatory networks for brute-force experimental testing, the system maintains reliable identification of conversion factors while dramatically improving efficiency and scalability.
2Adaptability or versatility
If embryonic stem cells are used for cell replacement therapy, then all cell types can be generated, but immune rejection and ethical concerns arise
Solution Approach 1:
The patent extracts the desired cell type generation capability from embryonic stem cells by using transdifferentiation of patient-specific somatic cells. This removes the immune rejection and ethical problems associated with ESCs while preserving the ability to generate any cell type needed for therapy.
Solution Approach 2:
The patent creates patient-specific copies of needed cell types by reprogramming the patient's own somatic cells through transdifferentiation. This produces immunologically matched cells that are genetically identical to the patient's cells, eliminating immune rejection concerns while maintaining full adaptability to generate any cell type.
3Object-affected harmful factors
If transdifferentiation is applied to generate patient-specific cells, then immune rejection risk is reduced, but the factors required for conversion are difficult to identify
Solution Approach 1:
The patent replaces difficult experimental factor identification with computational prediction systems that analyze gene expression data and regulatory networks. This substitution makes factor identification systematic, scalable, and much easier to perform while maintaining the ability to generate patient-specific cells with low immune rejection risk.
Solution Approach 2:
The patent introduces computational algorithms and predictive frameworks as intermediaries between the desire for patient-specific cells and the identification of conversion factors. These computational tools mediate the complex process of factor identification by prioritizing candidates based on bioinformatics analysis, making the overall process more tractable.
Data Source
AI summary
The invention relates to methods and compositions for converting one cell type to another cell type. Specifically, the invention relates to transdifferentiation of a cell to a different cell type. The invention relates to a method for determining the transcription factors required for conversion of a source cell to a cell exhibiting at least one characteristic of a target cell type. The invention also relates to method of reprogramming or forward programming a source cell.